More On

J&J may pay more than $1 billion in Risperdal case

Bloomberg reported the agreement late yesterday

According to a Bloomberg report last night, Johnson & Johnson (J&J) has agreed to pay more than $1 billion to end an investigation into the marketing of its antipsychotic drug Risperdal.

The U.S. government began the civil investigation against J&J in 2004 claiming the pharmaceutical company marketed Risperdal for unapproved uses. Risperdal, which used to be the company’s best-selling drug, had been approved by the Food and Drug Administration for some psychotic disorders, including schizophrenia.


Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.